287 related articles for article (PubMed ID: 12445287)
1. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
[TBL] [Abstract][Full Text] [Related]
2. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
[TBL] [Abstract][Full Text] [Related]
3. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
4. Multiple pathways to tumor immunity and concomitant autoimmunity.
Turk MJ; Wolchok JD; Guevara-Patino JA; Goldberg SM; Houghton AN
Immunol Rev; 2002 Oct; 188():122-35. PubMed ID: 12445286
[TBL] [Abstract][Full Text] [Related]
5. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
Hara I; Takechi Y; Houghton AN
J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
[TBL] [Abstract][Full Text] [Related]
6. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
Gaugler B; Olive D
Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
[TBL] [Abstract][Full Text] [Related]
7. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
Overwijk WW; Restifo NP
Crit Rev Immunol; 2000; 20(6):433-50. PubMed ID: 11396680
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 blockade: autoimmunity as treatment.
Kapadia D; Fong L
J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
[No Abstract] [Full Text] [Related]
9. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.
Colella TA; Bullock TN; Russell LB; Mullins DW; Overwijk WW; Luckey CJ; Pierce RA; Restifo NP; Engelhard VH
J Exp Med; 2000 Apr; 191(7):1221-32. PubMed ID: 10748239
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
Chianese-Bullock KA; Woodson EM; Tao H; Boerner SA; Smolkin M; Grosh WW; Neese PY; Merrill P; Petroni GR; Slingluff CL
J Immunother; 2005; 28(4):412-9. PubMed ID: 16000961
[TBL] [Abstract][Full Text] [Related]
11. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
13. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
14. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
15. Strategies and challenges in eliciting immunity to melanoma.
Ferguson AR; Nichols LA; Zarling AL; Thompson ED; Brinkman CC; Hargadon KM; Bullock TN; Engelhard VH
Immunol Rev; 2008 Apr; 222():28-42. PubMed ID: 18363993
[TBL] [Abstract][Full Text] [Related]
16. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK
J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608
[TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
18. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes.
Nichols LA; Chen Y; Colella TA; Bennett CL; Clausen BE; Engelhard VH
J Immunol; 2007 Jul; 179(2):993-1003. PubMed ID: 17617591
[TBL] [Abstract][Full Text] [Related]
19. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
[TBL] [Abstract][Full Text] [Related]
20. Antitumor vaccination using peptide based vaccines.
Eisenbach L; Bar-Haim E; El-Shami K
Immunol Lett; 2000 Sep; 74(1):27-34. PubMed ID: 10996624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
